|
1
|
Buscail L, Bournet B and Cordelier P: Role
of oncogenic KRAS in the diagnosis, prognosis and treatment of
pancreatic cancer. Nat Rev Gastroenterol Hepatol. 17:153–168.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kanno A, Masamune A, Hanada K, Kikuyama M
and Kitano M: Advances in early detection of pancreatic cancer.
Diagnostics (Basel). 9(18)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Unno M, Motoi F, Matsuyama Y, Satoi S,
Matsumoto I, Aosasa S, Shirakawa H, Wada K, Fujii T, Yoshitomi H,
et al: Randomized phase II/III trial of neoadjuvant chemotherapy
with gemcitabine and S-1 versus upfront surgery for resectable
pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol. 37 (Suppl
4)(S189)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Reni M, Balzano G, Zanon S, Zerbi A,
Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C,
Chiaravalli M, et al: Safety and efficacy of preoperative or
postoperative chemotherapy for resectable pancreatic adenocarcinoma
(PACT-15): A randomised, open-label, phase 2-3 trial. Lancet
Gastroenterol Hepatol. 3:413–423. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Uesaka K, Boku N, Fukutomi A, Okamura Y,
Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto
H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for
resected pancreatic cancer: A phase 3, open-label, randomised,
non-inferiority trial (JASPAC 01). Lancet. 388:248–257.
2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ocuin LM, Miller-Ocuin JL, Zenati MS,
Vargo JA, Singhi AD, Burton SA, Bahary N, Hogg ME, Zeh HJ III and
Zureikat AH: A margin distance analysis of the impact of adjuvant
chemoradiation on survival after pancreatoduodenectomy for
pancreatic adenocarcinoma. J Gastrointest Oncol. 8:696–704.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Raff JP, Noyer C, Boxer N, Sadan S, Costin
D, Roayaie S, Gordon M, Kaumaya M, Hopkins U, Cortese M, et al:
Early detection for pancreatic cancer in individuals at
elevated-risk, using endoscopic ultrasound (EUS) and magnetic
resonance imaging (MRI) of the abdomen: Feasibility and preliminary
outcomes. J Clin Oncol. 38 (Suppl 15)(e16798)2020.
|
|
8
|
Matsubayashi H, Takaori K, Morizane C,
Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S,
Suzuki M, et al: Familial pancreatic cancer: Concept, management
and issues. World J Gastroenterol. 23:935–948. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ohmoto A, Yachida S and Morizane C:
Genomic features and clinical management of patients with
hereditary pancreatic cancer syndromes and familial pancreatic
cancer. Int J Mol Sci. 20(561)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Llach J, Carballal S and Moreira L:
Familial pancreatic cancer: Current perspectives. Cancer Manag Res.
12:743–758. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Shin SJ, Park H, Sung YN, Yoo C, Hwang DW,
Park JH, Kim KP, Lee SS, Ryoo BY, Seo DW, et al: Prognosis of
pancreatic cancer patients with synchronous or metachronous
malignancies from other organs is better than those with pancreatic
cancer only. Cancer Res Treat. 50:1175–1185. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Eriguchi N, Aoyagi S, Hara M, Okuda K,
Tamae T, Fukuda S, Hashino K, Sato S, Fujiki K, Furukawa S and Jimi
A: Synchronous or metachronous double cancers of the pancreas and
other organs: Report on 12 cases. Surg Today. 30:718–721.
2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gerdes B, Ziegler A, Ramaswamy A, Wild A,
Langer P and Bartsch DK: Multiple primaries in pancreatic cancer
patients: Indicator of a genetic predisposition? Int J Epidemiol.
29:999–1003. 2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang Z, Zhou Y, Guan C, Ding Y, Tao S,
Huang X, Chen L, Zhang F and Zhang R: The impact of previous cancer
on overall survival of bladder cancer patients and the
establishment of nomogram for overall survival prediction. Medicine
(Baltimore). 99(e22191)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Brierley JD, Gospodarowicz MK and
Wittekind C (eds): TNM Classification of Malignant Tumours. 8th
edition. John Wiley & Sons, Toyama, Toyama, pp930-8550,
2017.
|
|
16
|
He X, Li Y, Su T, Lai S, Wu W, Chen L, Si
J and Sun L: The impact of a history of cancer on pancreatic ductal
adenocarcinoma survival. United European Gastroenterol J.
6:888–894. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hoshimoto S, Hishinuma S, Shirakawa H,
Tomikawa M, Ozawa I and Ogata Y: Outcomes in patients with
pancreatic cancer as a secondary malignancy: A retrospective
single-institution study. Langenbecks Arch Surg. 404:975–983.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Adamska A, Domenichini A and Falasca M:
Pancreatic ductal adenocarcinoma: Current and evolving therapies.
Int J Mol Sci. 18(1338)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Asari S, Matsumoto I, Toyama H, Shinzeki
M, Goto T, Ishida J, Ajiki T, Fukumoto T and Ku Y: Preoperative
independent prognostic factors in patients with borderline
resectable pancreatic ductal adenocarcinoma following curative
resection: The neutrophil-lymphocyte and platelet-lymphocyte
ratios. Surg Today. 46:583–592. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Iacobuzio-Donahue CA, Velculescu VE,
Wolfgang CL and Hruban RH: Genetic basis of pancreas cancer
development and progression: Insights from whole-exome and
whole-genome sequencing. Clin Cancer Res. 18:4257–4265.
2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Le A, Rajeshkumar NV, Maitra A and Dang
CV: Conceptual framework for cutting the pancreatic cancer fuel
supply. Clin Cancer Res. 18:4285–4290. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Neureiter D, Jäger T, Ocker M and
Kiesslich T: Epigenetics and pancreatic cancer: Pathophysiology and
novel treatment aspects. World J Gastroenterol. 20:7830–7848.
2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Guo M, Jia Y, Yu Z, House MG, Esteller M,
Brock MV and Herman JG: Epigenetic changes associated with
neoplasms of the exocrine and endocrine pancreas. Discov Med.
17:67–73. 2014.PubMed/NCBI
|
|
25
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Villarroel MC, Rajeshkumar NV,
Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH,
Eshleman JR, Klein A, Laheru D, et al: Personalizing cancer
treatment in the age of global genomic analyses: PALB2 gene
mutations and the response to DNA damaging agents in pancreatic
cancer. Mol Cancer Ther. 10:3–8. 2011.PubMed/NCBI View Article : Google Scholar
|
